Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 22.19.
Overvalued
The company’s latest PE is -1.31, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 102.15M shares, decreasing 2.01% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.49M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.45.